Silence Therapeutics Plc
Research Silence Therapeutics Plc (SLN) on Bullrun: market cap USD 509.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 509.66M
- Financial periodFY2025
- RevenueUSD 559.00K
- Revenue growth-98.7%
- Net income-USD 88.61M
- Free cash flow-USD 62.33M
- Gross margin61.5%
Valuation Snapshot
latest market cap is USD 509.66M.
About Silence Therapeutics Plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a);
Frequently asked questions
What is Silence Therapeutics Plc's market cap?
Silence Therapeutics Plc's market capitalization is USD 509.66M.
What does Silence Therapeutics Plc do?
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.